Patent ID: 8802827

Claim:
An isolated PCSK9-specific antagonist which comprises: (a) a heavy chain variable region comprising CDR1, CDR2 and CDR3 sequence, wherein (i) the CDR1 sequence is selected from the group consisting of: SEQ ID NO: 2 and residues 4-13 of SEQ ID NO: 2; (ii) the CDR2 sequence is selected from the group consisting of: SEQ ID NO: 9 and residues 4-20 of SEQ ID NO: 9; and (iii) the CDR3 sequence is selected from the group consisting of SEQ ID NO: 16 and residues 4-15 of SEQ ID NO: 16 and (b) a light chain variable region comprising CDR1, CDR2 and CDR3 sequence, wherein (i) the CDR1 sequence is SEQ ID NO: 24; (ii) the CDR2 sequence is SEQ ID NO: 31; and (iii) the CDR3 sequence is SEQ ID NO: 35; said antagonist which inhibits human PCSK9-dependent inhibition of cellular LDL uptake by at least 10%.